JP Morgan Chase
TXMD icon

JP Morgan Chase’s TherapeuticsMD TXMD Stock Holding History

JP Morgan Chase’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$583 Hold
293
– – ﹤0.01% 7168
2025
Q4 		$477 Hold
293
– – ﹤0.01% 7086
2025
Q3 		$310 Hold
293
– – ﹤0.01% 7085
2025
Q2 		$339 Sell
293
-20
-6% -$24 ﹤0.01% 6739
2025
Q1 		$290 Sell
313
-2
-0.6% -$2 ﹤0.01% 6756
2024
Q4 		$271 Buy
315
+22
+8% +$31 ﹤0.01% 6875
2024
Q3 		$486 Hold
293
– – ﹤0.01% 6803
2024
Q2 		$471 Hold
293
– – ﹤0.01% 6693
2024
Q1 		$671 Hold
293
– – ﹤0.01% 6682
2023
Q4 		$659 Sell
293
-20
-6% -$48 ﹤0.01% 6892
2023
Q3 		$945 Hold
313
– – ﹤0.01% 6651
2023
Q2 		$1.29K Sell
313
-50
-14% -$196 ﹤0.01% 6422
2023
Q1 		$1.19K Sell
363
-113
-24% -$542 ﹤0.01% 6479
2022
Q4 		$2K Buy
476
+163
+52% +$960 ﹤0.01% 6342
2022
Q3 		$2K Sell
313
-23
-7% -$186 ﹤0.01% 6270
2022
Q2 		$4K Sell
336
-4,769
-93% -$45.5K ﹤0.01% 6213
2022
Q1 		$97K Buy
5,105
+939
+23% +$14.8K ﹤0.01% 5525
2021
Q4 		$74K Sell
4,166
-2,303
-36% -$69K ﹤0.01% 5799
2021
Q3 		$240K Buy
6,469
+539
+9% +$23.9K ﹤0.01% 5140
2021
Q2 		$352K Sell
5,930
-7,310
-55% -$443K ﹤0.01% 4922
2021
Q1 		$887K Sell
13,240
-241
-2% -$18.9K ﹤0.01% 4321
2020
Q4 		$815K Sell
13,481
-249,853
-95% -$17.1M ﹤0.01% 4082
2020
Q3 		$21.2M Buy
263,334
+1,918
+0.7% +$153K ﹤0.01% 1457
2020
Q2 		$16.3M Sell
261,416
-124,156
-32% -$7.23M ﹤0.01% 1515
2020
Q1 		$20.4M Sell
385,572
-8,789
-2% -$871K ﹤0.01% 1244
2019
Q4 		$47.7M Sell
394,361
-3,845
-1% -$553K 0.01% 989
2019
Q3 		$72.3M Buy
398,206
+10,563
+3% +$1.49M 0.01% 784
2019
Q2 		$48.6M Sell
387,643
-21,070
-5% -$3.78M 0.01% 972
2019
Q1 		$99.5M Buy
408,713
+11,980
+3% +$3.17M 0.02% 645
2018
Q4 		$75.6M Sell
396,733
-18,584
-4% -$4.53M 0.02% 729
2018
Q3 		$136M Buy
415,317
+13,738
+3% +$4.21M 0.03% 577
2018
Q2 		$125M Buy
401,579
+8,088
+2% +$2.47M 0.03% 574
2018
Q1 		$95.8M Buy
393,491
+531
+0.1% +$149K 0.02% 652
2017
Q4 		$119M Sell
392,960
-47,597
-11% -$13.3M 0.03% 574
2017
Q3 		$113M Buy
440,557
+126,807
+40% +$36.7M 0.02% 576
2017
Q2 		$82.7M Buy
313,750
+39,233
+14% +$9.83M 0.02% 697
2017
Q1 		$98.8M Buy
274,517
+6,585
+2% +$2.04M 0.02% 634
2016
Q4 		$77.3M Buy
267,932
+51,418
+24% +$15.9M 0.02% 688
2016
Q3 		$73.7M Sell
216,514
-14,911
-6% -$5.45M 0.02% 674
2016
Q2 		$98.4M Buy
231,425
+66,159
+40% +$27.3M 0.02% 571
2016
Q1 		$52.9M Buy
165,266
+75,064
+83% +$25.6M 0.01% 785
2015
Q4 		$46.8M Sell
90,202
-11,441
-11% -$4.22M 0.01% 833
2015
Q3 		$29.8M Buy
101,643
+97,892
+2,610% +$34.8M 0.01% 1023
2015
Q2 		$1.47M Buy
3,751
+36
+1% +$12.7K ﹤0.01% 3082
2015
Q1 		$1.12M Buy
+3,715
New +$907K ﹤0.01% 3175
2013
Q4 		– Sell
-217
Closed -$32K – 4243
2013
Q3 		$32K Sell
217
-903
-81% -$109K ﹤0.01% 4291
2013
Q2 		$170K Buy
+1,120
New +$153K ﹤0.01% 4028

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's TXMD Position: Q1 2026 in Review

JP Morgan Chase held its TherapeuticsMD (TXMD) position steady in Q1 2026 at 293 shares worth $583. The position accounts for ﹤0.01% of the portfolio, ranked #7168.

JP Morgan Chase first reported a position in TXMD in Q2 2013 and has held it in 47 quarters since. The position peaked at $136M in Q3 2018. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • JP Morgan Chase held 293 shares of TherapeuticsMD worth $583 as of Q1 2026.
  • JP Morgan Chase left its TherapeuticsMD share count unchanged in Q1 2026.
  • TherapeuticsMD made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7168 holding.
  • JP Morgan Chase first reported a position in TherapeuticsMD in Q2 2013 and has held it in 47 quarters since.
  • JP Morgan Chase's TherapeuticsMD position peaked at $136M in Q3 2018.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.